Adlai Nortye (NASDAQ: ANL)
$1.49
(-7.4%)
-$0.12
Price as of July 14, 2025, 3:39 p.m. ET
Adlai Nortye Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Adlai Nortye Company Info
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.